Short answer
EyePoint, Inc. (EYPT) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $696,000 (down 97.2% year over year) with net income of −$85M.
Q1 2026 key financials · XBRL
- Revenue
- $696,000
- −97.2% YoY
- Net income
- −$85M
- −87.7% YoY
- Operating margin
- -12532.5%
- EPS (diluted)
- −$0.99
- −52.3% YoY
Source: XBRL data from the EyePoint, Inc. (EYPT) Q1 2026 10-Q on SEC EDGAR. USD.
EyePoint, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0.7M, down 97% YoY from $24.5M, driven by lower license and royalty income
- Operating margin -12,532.5% vs -199.7% YoY, with operating loss $87.2M vs $48.8M
- DURAVYU R&D spending $46.9M, up from $41.9M, the largest development program
- Cash and investments $222.5M at March 31, 2026, funding operations into Q4 2027
- Operating cash outflow $80.5M vs $53.1M YoY, with $60.1M from marketable-securities sales; DOJ settlement approximately $4.7M plus interest pending
Risk Factors
- New litigation risk triggered by March 20, 2026 complaint against Ocular Therapeutix over alleged false DURAVYU statements
- Regulatory risk from ongoing DOJ investigation, with EyePoint seeking a final negotiated resolution
- Competitive risk from new market products potentially affecting commercialization efforts and stock volatility
- Market risk from highly volatile trading and low volume limiting desired liquidation timing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other EyePoint, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.